Drug Trial Radar · NCT05736835
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
227
Actual
Start
Sep 21, 2023
Primary completion
Dec 16, 2025
Study completion Dec 16, 2025
Sponsor
- Lead sponsor
- CyanVac LLCIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants. The trial will enroll up to 400 healthy participants, age 18-80 years.
Conditions
- COVID-19
Interventions
CVXGABiological
CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety outcome measures (SAEs, AEs, and local and systemic reactogenicity)Time frame: day 1-8, day 1-29, and day 1-181 post vaccination
- ImmunogenicityTime frame: day 15 and day 29
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Velocity Clinical Research
San Diego, California
Velocity Clinical Research
Boise, Idaho
Velocity Clinical Research
Sioux City, Iowa
Velocity Clinical Research
Rockville, Maryland
Velocity Clinical Research
Omaha, Nebraska
University of Rochester
Rochester, New York
Velocity Clinical Research
Vestal, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Velocity Clinical Research
Providence, Rhode Island
Velocity Clinical Research
Cedar Park, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.